33 results on '"Devanand, Davangere P."'
Search Results
2. Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial
3. Intact global cognitive and olfactory ability predicts lack of transition to dementia
4. Donepezil Treatment in Patients With Depression and Cognitive Impairment on Stable Antidepressant Treatment: A Randomized Controlled Trial
5. Course and etiology of dysexecutive MCI in a community sample
6. Antidepressant Medication and Executive Dysfunction: A Deleterious Interaction in Late-Life Depression
7. Advancing Research on Care Needs and Supportive Approaches for Persons With Dementia: Recommendations and Rationale
8. Session 208 - Therapeutic Strategies in Depression with Cognitive Impairment
9. Provisional Diagnostic Criteria for Depression of Alzheimer Disease
10. Session 302 - Is Aging a Disease? Subjective Cognitive Impairment and Physiologic Factors
11. Obstructive Sleep Apnea and Risk of Mild Cognitive Impairment in Older Adults with Depression
12. INTACT GLOBAL COGNITIVE AND OLFACTORY ABILITIES PREDICT LACK OF TRANSITION TO DEMENTIA
13. ASSOCIATION OF APOE E2 GENOTYPE WITH NEUROPROTECTION: A TRANS-DIAGNOSTIC STUDY OF 1557 BRAINS IN THE NACC V 10 DATA BASE
14. VALACYCLOVIR TREATMENT OF ALZHEIMER’S DISEASE (VALAD): CLINICAL RATIONALE AND STUDY DESIGN
15. LITHIUM TREATMENT OF AGITATION IN ALZHEIMER’S DISEASE (LIT-AD): CLINICAL RATIONALE AND STUDY DESIGN
16. A SUMMARY OF THE RATIONALE AND DESIGN OF THE HARMONY STUDY: A PHASE 3 STUDY TO EVALUATE PIMAVANSERIN FOR THE TREATMENT OF HALLUCINATIONS AND DELUSIONS ASSOCIATED WITH DEMENTIA-RELATED PSYCHOSIS
17. THE S-CITAD STUDY: TRIAL DESIGN AND METHODS FOR THE S-CITALOPRAM IN AGITATION TRIAL
18. PLACEBO-CONTROLLED TRIAL OF DONEPEZIL FOLLOWING ANTIDEPRESSANT TREATMENT IN PATIENTS WITH COMORBID DEPRESSION AND COGNITIVE IMPAIRMENT
19. Research Update: Healthy Aging and Prevention of Late-Life Mood and Cognitive Disorders (Sponsored by the AAGP Research Committee; Chaired by Helen Lavretsky, M.D.)
20. Modifiable Risk Factors for Neurodegeneration
21. A placebo-controlled pilot discontinuation trial following haloperidol treatment of behavioral and psychotic symptoms in Alzheimer's disease
22. Open-label Treatment Of Combined Memantine Plus Escitalopram Treatment In Elderly Depressed Patients With Cognitive Impairment
23. Comparison of Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18F-FDG) PET in patients with Alzheimer's disease, Mild Cognitive Impairment and healthy controls
24. Comparison of Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18F-FDG) PET in patients with Alzheimer's disease, mild cognitive impairment, and healthy controls
25. P4-069: Olfactory identification deficits and mild cognitive impairment classification in a multiethnic community sample
26. P1-237: PET amyloid imaging with Pittsburgh compound B in Alzheimer's disease, mild cognitive impairment, and healthy controls
27. P1-267: The relation of depression to Alzheimer’s disease is not explained by vascular risk factors and stroke
28. #111 Intraperitoneal lipopolysaccharide produces changes in brain metabolic activity as measured by [ 18F]FDG in the rat
29. P3-089 A covariance resting PET pattern that discriminates between healthy elderly and early AD patients correlates with functional and cognitive severity in subjects with cognitive impairment but no dementia
30. P4-077 Predictive utility of apolipoprotein E genotype in cognitively impaired patients without dementia
31. P1-150 Olfactory identification deficits predict conversion to AD in cognitively impaired patients without dementia
32. P1-067 Predictive utility of five neuropsychological measures in outpatients with mild cognitive impairment
33. Olfactory deficits in mold cognitive impairment predict Alzheimer's disease on follow-up
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.